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Isoquinoline and quinazoline urea derivatives were found to bind to human adenosine A3
receptors. Series of N-phenyl-N′-quinazolin-4-ylurea derivatives and N-phenyl-N′-isoquinolin-
1-ylurea derivatives were synthesized and tested in radioligand binding assays on their
adenosine receptor affinities. A structure-affinity analysis indicated that on the 2-position of
the quinazoline ring or the equivalent 3-position of the isoquinoline ring a phenyl or heteroaryl
substituent increased the adenosine A3 receptor affinity in comparison to unsubstituted or
aliphatic derivatives. Furthermore, the structure-affinity relationship of substituted phenylurea
analogues was investigated. Substituents such as electron-withdrawing or electron-donating
groups were introduced at different positions of the benzene ring to probe electronic and
positional effects of substitution. Substitution on the 3- or 4-position of the phenyl ring decreased
the adenosine A3 receptor affinity. Substitution at position 2 with an electron-donating
substituent, such as methyl or methoxy, increased human adenosine A3 receptor affinity,
whereas substitution on the 2-position with an electron-withdrawing substituent did not
influence affinity. Combination of the optimal substituents in the two series had an additive
effect, which led to the potent human adenosine A3 receptor antagonist N-(2-methoxyphenyl)-
N′-(2-(3-pyridyl)quinazolin-4-yl)urea (VUF5574, 10a) showing a Ki value of 4 nM and being at
least 2500-fold selective vs A1 and A2A receptors. Compound 10a competitively antagonized
the effect of an agonist in a functional A3 receptor assay, i.e., inhibition of cAMP production in
cells expressing the human adenosine A3 receptor; a pA2 value of 8.1 was derived from a Schild
plot. In conclusion, compound 10a is a potent and selective human adenosine A3 receptor
antagonist and might be a useful tool in further characterization of the human A3 receptor.
Introduction
Extracellular adenosine exerts its physiological effects
by activation of cell membrane-spanning receptors
called P1-purinoceptors. The P1-purinoceptors are di-
vided into three subtypes: A1, A2, and A3, with A2
further subdivided into A2A and A2B. All four receptors
are coupled via a G protein to the adenylate cyclase-
cAMP signal transduction pathway. Activated adeno-
sine A1 and A3 receptors inhibit adenylate cyclase,
whereas A2A and A2B receptors stimulate this enzyme.
The target receptor in the present study, the human
adenosine A3 receptor, is mainly expressed in lung, liver,
kidney, and heart but is also found in the CNS, testes,
and immune system.1-3
Selective adenosine A3 antagonists are putative an-
tiinflammatory, antiasthmatic, or antiischemic agents.4-9
Xanthines, although versatile leads for antagonists of
the adenosine A1 and A2A receptors, are much less
potent at the adenosine A3 receptor.10 For this reason
library screening was used to search for novel leads.
Triazolonaphthpyridine,11,12 1,4-dihydropyridines13-15
and pyridines,16 triazoloquinazolines,17,18 isoquinolines
and quinazolines,19,20 and flavonoids21 were identified
as adenosine A3 receptor ligands this way, and chemical
optimization of the leads yielded selective adenosine A3
receptor antagonists.
Recently we have reported on a series of isoquinoline
and quinazoline analogues as adenosine A3 receptor
ligands.19,20 From these studies we concluded that
higher adenosine A3 receptor affinity resulted from
spacer-coupled aromatic groups on the 1-position of the
isoquinoline ring (Figure 1). By altering the aromatic
substitution pattern, selectivity for the adenosine A3
receptor was obtained. We have since extended the
scope of our investigations into this class of compounds
and found that a urea moiety as spacer also provided
an increase in binding affinity compared to a directly
coupled aromatic group on the 1-position of the iso-
quinoline ring. In this new series, the influence on
adenosine A3 receptor affinity of substituents at the
2-position of phenylurea quinazolines was investigated
first. Subsequently, the influence of substitution of the
phenylurea moiety was analyzed. Finally, computer-
aided visualization of common elements within the
isoquinoline and quinazoline series was used to derive
clues for their high affinity.
Chemistry
The preparation of compounds 5a-k was performed
following the general synthetic strategy depicted in
Scheme 1. The intermediates 4a-k were synthesized
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initially based on a method described by Linschoten et
al.22 with some modifications. Treatment of 2-amino-
benzonitrile (1) with strong base yielded a relatively
stable anion as intermediate. This nucleophile reacted
with nitriles 3a-k, and after hydrolysis the quinazoline
derivatives 4a-k were obtained. The yield of the
derivatives was dependent on the bulkiness of substit-
uents R1 of nitriles 3a-k due to steric hindrance in the
nucleophilic attack of the anion. In such a case the anion
could react with the starting nitrile 1 which, after
hydrolysis, yielded the dimeric side product 2-(2-ami-
nophenyl)-4-quinazolineamine (2). This agrees with the
findings of Taylor and Borror23 who suggested that in
the case of different aminobenzonitriles the critical
factor determining dimerization was the ability of the
nitrile group to undergo nucleophilic attack rather than
the basicity of the attacking amino group. The course
of the condensation reaction’s dependence on the acces-
sibility of the participating nitrile group to undergo
nucleophilic attack was clearly demonstrated by a
mixture of 1 and trimethylacetonitrile (3c), which
yielded only dimer 2. The method of Smyrl and Smith-
wick24 with sodium hydroxide as catalyst also failed
with reactants 1 and 3c. However, method B favored
the formation of 4c over 2. In method B sodium hydride
was used as base, so the formation of the anion was
completed before nitrile 3 was added. With method A,
an equilibrium could exist between 1 and the anion,
which can compete with nitrile 3, resulting in the
formation of 2. Good yields were also reached with
method B in the synthesis of 4e, although the nitrogen
in 3e on the meta position is not able to delocalize the
negative charge originating from the nucleophilic attack
of the anion of 1. Shishoo et al.25 have described a
hydrogen chloride-catalyzed reaction of 2-aminoben-
zonitrile with acetonitrile yielding 63% of 4-amino-2-
methylquinazoline. However, an examination of this
method using trimethylacetonitrile (3c) revealed that
neither desired product nor side product was formed.
These authors have described that the electron-with-
drawing ability of the substituent on the nitrile did not
affect the course of the reaction, and from our results
we suggest that the steric factor plays a dominant role,
both in the base-catalyzed reaction and in the acid-
catalyzed reaction.
Finally, derivatives 5a-k were prepared by reaction
of phenyl isocyanate (7i) with 4-aminoquinazolines 4.
The substituted phenylurea derivatives 9a-h as well
as compounds 8, 10, and 11 were prepared as depicted
in Scheme 2. Reaction of quinazolines 4 and isoquino-
lines 6 in dry acetonitrile at 30-50 °C with the ap-
propriate isocyanate 7a-i afforded the products 8-11
in good overall yields. The low solubility of the products
in acetonitrile simplified the isolation and purification.
For this reason, we favor this method26 above reaction
in refluxing dry THF.27 The yields, method used, and
analytical data of amines 4 and 6 and products 5 and
8-11 are summarized in Table 1.
Results and Discussion
Binding Studies. All synthesized compounds were
tested in radioligand binding assays to determine their
affinities at adenosine A3, A1, and A2A receptors. The
affinities at adenosine A1 and A2A receptors were
determined on rat brain cortex and rat striatum with
[3H]DPCPX and [3H]CGS 21680 as radioligands, re-
spectively.28,29 The affinity at adenosine A3 receptors
was determined on membranes from HEK 293 cells,
stably expressing the human A3 receptor, using [125I]-
AB-MECA.30,31 The results are shown in Tables 2-4.
Preliminary SAR. In previous studies we have
described isoquinoline and quinazoline derivatives as
a novel class of ligands for the adenosine A3 receptor.19,20
An aromatic ring, coupled by a conjugated spacer to the
1-position of the isoquinoline ring, proved beneficial for
high adenosine A3 receptor affinity. All spacers were
three bond lengths long (Figure 1). In the present study
we prolonged the spacer with one extra atom, thus
introducing a urea moiety as spacer.
Comparison of the affinities of compounds containing
the four different spacers (Table 2) revealed that com-
pound 12, bearing an amidine group as spacer, and com-
pound 13, containing a ketone spacer, showed moderate
affinity at the adenosine A3 receptor, whereas com-
pounds with an amide and especially those with a urea
moiety had higher adenosine A3 receptor affinities. Com-
pound 8b with a urea spacer showed the highest A3
selectivity. These data led us to explore the urea
derivatives further.
In our previous studies20 it had been shown that iso-
quinolines differ only slightly from quinazolines in their
affinities at adenosine receptors. To check whether this
also held in the urea series, we synthesized and deter-
mined the affinity of quinazolines 5a,b,d and isoquino-
lines 8a,b,d (Table 3). The results proved to be some-
what ambiguous. Quinazolines within the unsubstituted
derivatives 5a and 8a and the phenyl derivatives 5d
and 8d had increased adenosine A3 receptor affinities,
whereas 2-pyridyl derivatives 5b and 8b showed the op-
posite effect. In view of the better accessibility of 4-ami-
noquinazolines compared to the 1-aminoisoquinolines,
we decided to focus on the quinazoline derivatives only.
Optimization of the Substituent on the 2-Posi-
tion. All isoquinolines and quinazolines described so far
as ligands for the adenosine A3 receptor have a 2-pyridyl
group on the 3-position of the isoquinoline ring or the
equivalent 2-position of the quinazoline ring, respec-
tively. In the present study, we investigated the influ-
ence of other substituents on this position, and therefore
we synthesized compounds 5a-k (Table 3).
Quinazoline 5a, being unsubstituted at position 2, had
low adenosine A3 receptor affinity. Substitution with a
bulky tert-butyl group at position 2 was unfavorable
Figure 1. Isoquinolines and quinazolines as human adenosine
A3 receptor ligands.
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(5c). However, substitution with an aromatic group
resulted in a largely increased adenosine A3 receptor
affinity (compounds 5b,d-f). Within this group of
compounds, some differences in adenosine A3 receptor
affinity were observed. The phenyl group of 5d and the
2-pyridyl and 4-pyridyl groups of compounds 5b,f,
respectively, contributed almost equally to adenosine A3
receptor affinity, whereas the 3-pyridyl group (deriva-
tive 5e) increased the affinity several times.
o-Methyl substitution of the 2-pyridyl group as in 5g
was allowed. However, a 4,6-dimethylpyrimidinyl sub-
stituent yielded modestly active 5h. The furyl analogue
(5i) showed affinity and selectivity at adenosine recep-
tors very similar to those of the phenyl and 2- and
4-pyridyl derivatives. Next, 2-substitution of the quinazo-
line ring with an amine functionality was investigated.
The pyrrolidine derivative 5k and the diethylamine
derivative 5j both possessed relatively high adenosine
A3 receptor affinity. This relatively high adenosine A3
receptor affinity of the amine-substituted compounds
5j,k could not be caused by their high lipophilicity,
because compound 5c, bearing the most lipophilic
substituent within this series (tert-butyl), was inactive
at the adenosine A3 receptor. The high adenosine A3
receptor affinity of compounds 5j,k may be due to the
lone pair of the nitrogen atom, which may have a similar
electrostatic interaction with the receptor as the ð-elec-
trons of an aromatic ring. This might explain the low
affinity of the unsubstituted compound 5a and the
aliphatic derivative 5c. Interestingly, compound 5j
showed also high adenosine A1 receptor affinity, even
being slightly A1 selective.
In conclusion, substituents at position 2 of the quinazo-
line ring that are relatively small and possess a high
electron density imposed moderate to high adenosine
A3 receptor affinity in this series of quinazolines.
Substituent Effect of Phenylurea. In an approach
according to Topliss for aromatic compounds,32 a series
of phenylurea-substituted N-aryl-N′-(2-phenylquinazol-
4-yl)urea derivatives were synthesized. All compounds
were tested on their adenosine receptor affinities (Table
4). The substituted compounds 9a-d showed highly
decreased adenosine A3 receptor affinity compared to
the unsubstituted derivative 5d.
The potent and subtype-selective adenosine A3 recep-
tor antagonist VUF8504 (15; Figure 2) bears a 4-meth-
oxy substituent20 and differs from the present compound
9d in the spacer and the heterocyclic ring. Most prob-
ably, the length (and thus the substituent direction) of
the amide and urea spacer contribute to the observed
large difference. Therefore we investigated the 2- and
3-methoxy derivatives (9f,e, respectively) and compared
them with the 4-methoxy derivative (9d).
The 3-methoxy derivative 9e showed adenosine A3
receptor affinity with a Ki value in the low micromolar
range, whereas the 2-methoxy analogue VUF5386 (9f)
had high adenosine A3 receptor affinity with a Ki value
of 87 nM (Table 4). The large difference in adenosine
receptor affinities between 9d,f is very remarkable.
Since the electronic influence of ortho and para substi-
tution is comparable, the steric aspects may be respon-
sible for the observed difference.
Next, we examined the influence of another electron-
donating substituent at the ortho position (Me, 9h) as
well as an electron-withdrawing substituent (Cl, 9g) at
this position. The affinities of compounds 9f-h are in
agreement with the electronic effect of the 4-substituted
3-(2-pyridyl)isoquinolin-1-ylbenzamides described before:
20 i.e., electron-withdrawing substituents did not influ-
ence adenosine A3 receptor affinity compared to the
unsubstituted phenyl derivative, while electron-donat-
ing substituents increased adenosine A3 receptor affin-
ity. This suggests a comparable type of interaction
between the adenosine A3 receptor and the substituents
on both positions. We tried to visualize this by molecular
modeling studies (next section).
Finally, the substituents of the most potent com-
pounds of Tables 3 and 4 were combined in derivatives
10 in order to design active adenosine A3 receptor
antagonists. The substituent effects were found to be
additive in compounds 10a,b. Both compounds were
very active, and again, the methoxy derivative showed
Scheme 1a
a R1 is defined in Table 1.
Scheme 2a
a R1 and R2 are defined in Table 1.
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Table 1. Yields and Analytical Data of Isoquinoline and Quinazoline Analogues
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the highest affinity. This led to VUF5574 (10a), a potent
human adenosine A3 receptor antagonist with a Ki value
of 4 nM and at least 2500-fold selectivity over A1 and
A2A receptors.
We also synthesized compound 11, since isoquinolines
and quinazolines described earlier also contained a
2-pyridyl group. Compound 11 is also a high-affinity
human adenosine A3 receptor antagonist but showed a
7-fold decrease in affinity compared to 10a. This agrees
with the earlier finding (derivatives 5b,e) that in these
quinazoline urea series a 3-pyridyl group is preferred
over the 2-pyridyl group.
QSAR. We attempted some quantitative approaches
to elucidate the relationships between the substit-
uents at the 2-position of the quinazoline ring and the
affinities. A similar approach was followed for substit-
uents at the 2-position of the phenyl. We performed
correlation analyses using various substituent param-
eters describing steric, electronic, and lipophilic proper-
ties. However, no correlation was found in the first
series of compounds (compounds 5a-k) and neither
between (log P)2 and the pKi in contrast to the pyridine
derivatives described as antagonists for the adenosine
A3 receptor.16
Molecular Modeling. Similar phenyl substituents
in the urea and benzamide series led to comparable
affinities (comparison of 2- and 4-substituents and
3-substituents).20 This suggests a common binding site
for the benzamide and phenylurea substituents. The
structures of 4-methoxy-N-[3-(2-pyridyl)isoquinolin-1-
yl]benzamide (15)20 and N-(2-methoxyphenyl)-N′-[2-(3-
pyridyl)quinazolin-4-yl]urea (10a; Figure 2) were built
and minimized. From energy minimizations with mo-
lecular mechanics, four conformations emerged, each
with the nitrogen of the pyridine ring “upwards”, i.e.,
in the opposite direction of the spacer. In all four
conformations the isoquinoline and quinazoline ring
showed planarity with the spacer, whereas the pyridyl
group was slightly turned out of the plane. The differ-
ences between the four conformations are due to two
possible orientations of the pyridyl group and two
possible orientations of the phenyl ring.
Table 1 (Continued)
Table 2. Adenosine Receptor Subtype Affinities of Isoquinoline Derivatives with Different Spacers
a Displacement of specific [125I]AB-MECA binding at human adenosine A3 receptors expressed in HEK 293 cells, expressed as Ki (
SEM in nM (n ) 3-5). b Displacement of specific [3H]DPCPX binding in rat brain cortical membranes, expressed as percentage displacement
of specific binding at a concentration of 10 íM (n ) 2-3) or Ki ( SEM in íM (n ) 3). c Displacement of specific [3H]CGS 21680 binding
in rat striatal membranes, expressed as percentage displacement of specific binding at a concentration of 10 íM (n ) 2-3).
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Subsequently, we aimed for matching of both the
methoxy group and the pyridyl ring of the two com-
pounds. Of the possible fits no one showed planarity of
both the phenylurea and benzamide and the isoquino-
line and quinazoline rings. The superimposition of
compounds 15 and 10a, with best possible matching of
the nitrogens of the pyridine substituents as well as the
methoxy groups, is depicted in Figure 3. This relatively
poor fit shows that a comparable conformation of 15 and
10a in their receptor interaction is not self-evident. The
superimposition in Figure 3 shows that both compounds
may bind at a common binding site but full overlap is
not feasible. This suggests that more space in the
receptor pocket exists than is being used, thus giving
room for further synthetic efforts.
Functional Assay at Adenosine A3 Receptors. For
a functional evaluation intact cells expressing the
human adenosine A3 receptor were used. The inhibition
of forskolin-stimulated cAMP production by receptor
agonists was used as a read-out. NECA dose-response
curves were recorded (n ) 4) in the absence and
presence of three increasing concentrations of 10a
(Figure 4). Compound 10a caused a rightward shift of
the dose-response curves; a pA2 value of 8.1 was
Table 3. Adenosine Receptor Affinities of 3-Substituted N-Phenyl-N′-(3-R-isoquinolin-1-yl)urea Derivatives and 2-Substituted
N-Phenyl-N′-(2-R-quinazolin-4-yl)urea Derivatives
a Displacement of specific [125I]AB-MECA binding at human adenosine A3 receptors expressed in HEK 293 cells, expressed as Ki (
SEM in nM (n ) 3-5) or percentage displacement of specific binding at a concentration of 10 íM (n ) 2). b Displacement of specific
[3H]DPCPX binding in rat brain cortical membranes, expressed as percentage displacement of specific binding at a concentration of 10
íM (n ) 2-3) or Ki ( SEM in nM (n ) 3). c Displacement of specific [3H]CGS 21680 binding in rat striatal membranes, expressed as
percentage displacement of specific binding at a concentration of 10 íM (n ) 2-3).
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calculated from a Schild plot (inset Figure 4). The slope
of the Schild plot was not significantly different from
unity, suggesting the competitive nature of 10a. This
value is in good agreement with the results from binding
studies (pKi ) 8.4, Table 4).
Conclusions
In this study, we report on isoquinoline and quinazo-
line urea analogues as antagonists of the human ad-
enosine A3 receptor. From a series of N-phenyl-N′-
quinazolin-4-ylurea derivatives we conclude that an
aromatic group or an amine at the 2-position of the
quinazoline ring is necessary for adenosine A3 receptor
affinity. Second, the effects of substitution on the
phenylurea moiety were investigated. Substitution at
the 3- or 4-position of the phenyl ring decreased the
Table 4. Adenosine Receptor Affinities of Substituted Quinazol-4-yl- and Isoquin-1-ylurea Derivatives
a Displacement of specific [125I]AB-MECA binding at human adenosine A3 receptors expressed in HEK 293 cells, expressed as Ki (
SEM in nM (n ) 3-5) or percentage displacement of specific binding at a concentration of 10 íM (n ) 2). b Displacement of specific
[3H]DPCPX binding in rat brain cortical membranes, expressed as percentage displacement of specific binding at a concentration of 10
íM (n ) 2-3) or Ki ( SEM in nM (n ) 3). c Displacement of specific [3H]CGS 21680 binding in rat striatal membranes, expressed as
percentage displacement of specific binding at a concentration of 10 íM (n ) 2-3).
Figure 2. Most potent A3 ligands of the benzamide and urea
series of isoquinolines and quinazolines at the human adeno-
sine A3 receptor.
Figure 3. Fit of A3 antagonists 10a and 15 (in the plane of
the isoquinoline and quinazoline rings (left) or 90° rotated
(right)).
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affinity, whereas an electron-withdrawing substituent
on position 2 did not influence the binding. However,
2-substitution with the electron-donating substituents
methyl or methoxy increased human adenosine A3
receptor affinity.
Combination of the optimal substituents in both series
as in 5e (3-pyridyl) and 9f (2-methoxyphenylurea) led
to 10a. In binding studies it showed a Ki value of 4 nM.
Functional antagonism was demonstrated in an assay
consisting of agonist-induced inhibition of adenylate
cyclase. The pA2 value of compound 10a, derived from
a Schild plot, was 8.1. Thus, VUF5574 (10a) is a very
active human adenosine A3 receptor antagonist and is
highly selective vs adenosine A1 and A2A receptors. This
potent new human adenosine A3 receptor antagonist
might be a useful tool for pharmacological characteriza-
tion of the A3 receptor.
Experimental Section
Abbreviations: APT, attached proton test; CGS15943,
9-fluoro-2-(2-furyl)-5,6-dihydro[1,2,4]triazolo[1,5-c]quinazin-5-
imine; CI, chemical ionization; COSY, correlated spectroscopy;
DEPT, distortionless enhancement by polarization transfer;
DMEM, Dulbecco’s minimal essential medium; [3H]DPCPX,
[3H]-1,3-dipropyl-8-cyclopentylxanthine; [3H]CGS 21680,
[3H]-2-[[4-(2-carboxyethyl)phenyl]ethylamino]-5′-N-(ethylcar-
bamoyl)adenosine; HEK cells, human embryonic kidney cells;
HEPES, 4-(2-hydroxethyl)-1-piperazineethanesulfonic acid;
HMPT, hexamethylphosphoric triamide; [125I]AB-MECA,
[125I]-N6-(4-amino-3-iodobenzyl)-5′-(N-methylcarbamoyl)ade-
nosine; Ki, equilibrium inhibition constant; L-249313, 6-car-
boxymethyl-5,9-dihydro-9-methyl-2-phenyl[1,2,4]triazolo[5,1-
a][2,7]naphth-pyridine; NECA, 5′-(N-ethylcarbamoyl)adenosine;
SPAP cells, secreted placental alkaline phosphatase; XAC,
8-[4-(((((2-aminoethyl)amino)carbonyl)methoxy)oxy)phenyl]-
1,3-dipropylxanthine.
Materials. 6-Methylpyridine-2-carbonitrile was purchased
from LONZA Inc. (France). 4,6-Dimethylpyrimidine-2-carbo-
nitrile was commercially available from SALOR (Austria).
Acetonitrile was purchased from J.T. Baker (The Netherlands).
1-Aminoisoquinoline (6a), 4-chlorophenyl isocyanate, 3,4-
dichlorophenyl isocyanate, 2-furonitrile, and o-tolyl isocyanate
were commercially available from Aldrich (The Netherlands).
Benzyl cyanide, 3-cyanopyridine, 4-cyanopyridine, diethylami-
noacetonitrile, 2-methoxyphenyl isocyanate, 3-methoxyphenyl
isocyanate, 4-methoxyphenyl isocyanate, phenyl isocyanate,
1-pyrrolidinecarbonitrile, p-tolyl isocyanate, and trimethylac-
etonitrile were purchased from ACROS (Belgium). THF was
predried over CaCl2 and distilled from LiAlH4. DMF was dried
by a passage through a column of Al2O3 and acetone was
distilled from K2CO3. All other solvents used were of analytical
grade. 4-Amino-2-(2-pyridinyl)quinazoline (4b) was prepared
as described by Linschoten et al.22 1-Amino-3-(2-pyridinyl)-
isoquinoline (6b) and 1-amino-3-phenylisoquinoline (6d) were
available from stock (Vrije Universiteit, Amsterdam).
Synthesis. 1H and 13C NMR spectra were recorded on a
Bruker AC 200 (1H NMR, 200 MHz; 13C NMR, 50.29 MHz)
spectrometer with tetramethylsilane or sodium 3-(trimethyl-
silyl)propionate as an internal standard. 2D-NMR (H-H and
C-H) COSY techniques were frequently used to support
interpretation of 1D spectra. The multiplicity of the carbon
signals was determined by DEPT or APT spectra or by a
combination of a normal decoupled carbon spectrum and a CH
correlation. The symbols used are (p) for primary, (s) for
secondary, (t) for tertiary and (q) for quaternary carbon signals.
Melting points were measured on a Electrothermal IA9200
apparatus. Elemental analysis were performed by the analyti-
cal department of Organic and Molecular Inorganic Chemistry
at the University of Groningen (The Netherlands) and are
within (0.4% of theoretical values unless otherwise specified.
Reactions were routinely monitored by thin layer chromatog-
raphy on Merck silica gel F254 plates and spots were visualized
with UV light at 254 nm or iodine or aqueous potassium
permanganate staining.
General Procedure for the Preparation of 4a,c-k.
Method A. To a solution of 10.37 g (88.00 mmol) of 2-ami-
nobenzonitrile in anhydrous dioxane (100 mL) was added 1
equiv (4.75 g, 88.0 mmol) of freshly prepared sodium methoxide
and the mixture stirred under a nitrogen atmosphere over-
night. When all of the sodium methoxide had dissolved a
solution of 1 equiv of the appropriate carbonitrile in 30 mL of
anhydrous dioxane was added dropwise and refluxed for 16
h. After cooling the reaction mixture was hydrolyzed with 15
mL of water. Two equivalents (300 mL, 0.6 M) of HCl were
added and the water layer was extracted with chloroform (3
 150 mL). After neutralization of the solution with K2CO3,
the product was extracted with 100 mL of chloroform (5  100
mL). The combined organic layers were washed with brine,
dried over sodium sulfate, and evaporated to dryness. The
residue was crystalized.
Method B. A solution of 24.0 g (200 mmol) of 2-aminoben-
zonitril in 70 mL of THF was added dropwise to a suspension
of 9.60 g (240 mmol) sodium hydride and 250 mL of anhydrous
THF under a nitrogen atmosphere at 0 °C. After slow warming
to room temperature 50 mL of the appropriate carbonitrile 3
Figure 4. Inhibition of adenylate cyclase in cells stably transfected with human adenosine A3 receptors. Data were taken from
a typical experiment. The assay was carried out as described in the Experimental Section (in the presence of 10 íM forskolin).
Dose-response curves of NECA were recorded in the absence and presence of three concentrations of antagonist 10a. The pA2
value was determined from a Schild plot (inset). In the Schild plot each data point is shown as mean ( SEM for four determinations.
The ligands were: solid squares, NECA; open triangles, NECA + 10a (10 nM); solid diamonds, NECA + 10a (30 nM); open
circles, NECA + 10a (100 nM).
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(400 mmol) or a solution of carbonitrile in dry THF was added
dropwise under stirring and refluxed for 20 h. After cooling
the reaction mixture was hydrolyzed with 25 mL of water and
1 equiv of HCl was added. The organic solvent was evaporated
and 500 mL of water and 100 mL of chloroform were added to
the resulting residue. The mixture was neutralized with 1.5
M NaOH and three times extracted with 100 mL of chloroform
or ethyl acetate. The combined organic layers were dried over
sodium sulfate and evaporated to dryness. The residue was
purified by crystallization or sublimation.
4-Aminoquinazoline (4a). Method A. Extraction was
carried out with ethyl acetate and purification by column
chromotagraphy using EA as eluent: yield 74%; mp 274-275
°C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä 7.48
(ddd, 3J65 ) 7.9 Hz, 3J67 ) 6.8 Hz, 4J68 ) 1.2 Hz, 1H, H6), 7.61-
7.79 (m, 4H, H7, H8 & NH2), 8.21 (d, 3J56 ) 8.0 Hz, 1H, H5),
and 8.37 (s, 1H, H2).
2-(1,1-Dimethylethyl)-4-aminoquinazoline (4c). Method
B. Extraction with chloroform and purification by sublimation
at 0.5 Torr and 145 °C: yield 6.42 g (16%) white needles; mp
178 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä
1.34 (s, 9H, CH3), 7.40 (ddd, 3J65 ) 8.1 Hz, 3J67 ) 7.0 Hz, 4J68
) 1.6 Hz, 1H, H6), 7.59 (bs, 2H,NH2), 7.60-7.74 (m, 2H, H7
and H8), and 8.16 (d, 3J56 ) 8.1 Hz, 1H, H5); 13C NMR (DMSO)
29.33 CH3 (p) 38.52 C(CH3)3 (q) 112.4 C10 (q) 123.1 C7 (s) 124.2
C6 (s) 127.2 C8 (s) 132.1 C5 (s) 149.8 C9 (q) 161.5 C2 (q) 172.3
C4 (q).
2-Phenyl-4-aminoquinazoline (4d). Method A. Extraction
with ethyl acetate and purification by crystallization from EA/
Et2O: yield 54%; mp 146 °C; 1H NMR (DMSO-d6, ref DMSO-
d5-H ) 2.49 ppm) ä 7.43-7.51 (m, 4H, ArH & H6), 7.67-7.85
(m, 4H, H7, H8 & NH2), 8.12-8.37 (m, 1H, H5), and 8.38-
8.48 (m, 2H, ArH).
2-(3-Pyridyl)-4-aminoquinazoline (4e). Method B: yield
86%; mp 185-188 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H )
2.49 ppm) ä 7.35-7.46 (m, 2H, H5′ & H6), 7.78-7.83 (m, 2H,
H8 & H7), 7.98 (bs, 2H, NH2), 8.27 (d, 3J56 ) 8.2 Hz, 1H, H5),
8.66-8.72 (m, 2H, H4′ & H6′), and 9.56 (s, 1H, H2′).
2-(4-Pyridyl)-4-aminoquinazoline (4f). Method A: yield
68%; mp 292-294 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H )
2.49 ppm) ä 7.49-7.60 (m, 1H, H6), 7.81-7.87 (m, 2H, H8 &
H7), 8.02 (bs, 2H, NH2), 8.26-8.31 (m, 3H, H5 & AA′BB′ H3′),
8.73 (dd, 3JAB ) 4.5 Hz, 4JAA′ ) 1.4 Hz, 2H, AA′BB′ H2′).
2-(6-Methyl-2-pyridyl)-4-aminoquinazoline (4g). Method
B: yield 36%; mp 200-202 °C; 1H NMR (DMSO-d6, ref DMSO-
d5-H ) 2.49 ppm) ä 2.55 (s, 3H, CH3), 7.31 (d, 3J5′4′ ) 7.5 Hz,
1H, H5′), 7.45-7.56 (m, 1H, H6), 7.74-7.83 (m, 3H, H4′, H8
& H7), 7.99 (s, 2H, NH2), 8.21 (d, 3J3′4′ ) 7.7 Hz, 1H, H3′), and
8.28 (d, 3J56 ) 8.2 Hz, 1H, H5).
2-(4,6-Dimethylpyrimidin-2-yl)-4-aminoquinazoline (4h).
Method B: yield 29%; mp 219 °C; 1H NMR (DMSO-d6, ref
DMSO-d5-H ) 2.49 ppm) ä 2.50 (s, 6H, CH3), 7.32 (s, 1H, H5′),
7.50-7.58 (m, 1H, H6), 7.80-7.81 (m, 2H, H7 & H8), 8.00 (s,
2H, NH2), and 8.27 (d, 3J56 ) 8.2 Hz, 1H, H5).
2-(2-Furyl)-4-aminoquinazoline (4i). Method A: yield
51%; mp 232-233 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H )
2.49 ppm) ä 6.64 (dd, 3J4′5′ ) 3.4 Hz, 3J4′3′ ) 1.8 Hz, 1H, H4′)
7.18 (dd, 3J5′4′ ) 3.3 Hz, 4J5′3′ ) 0.8 Hz, 1H, H5′), 7.44 (ddd,
3J65 ) 8.0 Hz, 3J67 ) 6.5 Hz, 4J68 ) 1.8 Hz, 1H, H6), 7.66-7.80
(m, 3H, H3′, H8, and H7), 7.84 (bs, 2H, NH2), 8.20 (d, 3J56 )
7.9 Hz, 1H, H5).
2-Diethylamino-4-aminoquinazoline (4j). Method A: yield
23%; mp 247-249 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H )
2.49 ppm) ä 1.11 (t, 3J ) 7.0 Hz, 6H, CH3), 3.60 (q, 3J ) 7.0
Hz, 4H, CH2), 6.96 (ddd, 3J65 ) 8.1 Hz, 3J67 ) 6.9 Hz, 4J68 )
1.2 Hz, 1H, H6), 7.19-7.36 (m, 3H, H8 & NH2), 7.45 (ddd, 3J78
) 8.4 Hz, 3J76 ) 6.9 Hz, 4J75 ) 1.4 Hz, 1H, H7), and 7.93 (dd,
3J56 ) 8.1 Hz, 4J57 ) 1.0 Hz, 1H, H5).
2-(Pyrrolidin-1-yl)-4-aminoquinazoline (4k). Method
A: yield 34%; mp 325 °C dec; 1H NMR (DMSO-d6, ref DMSO-
d5-H ) 2.49 ppm) ä 1.88 (t, 3J ) 6.5 Hz, 4H, CH2), 2.50 (t, 3J
) 6.5 Hz, 4H, CH2), 6.97 (dd, 3J65 ) 8.2 Hz, 3J67 ) 6.7 Hz, 1H,
H6), 7.23-7.39 (m, 3H, H8 & NH2), 7.48 (dd, 3J78 ) 8.4 Hz,
3J76 ) 6.8 Hz, 1H, H7), and 7.94 (dd, 3J56 ) 8.4 Hz, 1H, H5).
General Procedure for the Preparation of 5a-k. One
equivalent of quinazolineamine 4 was dissolved in acetonitrile
at 20-50 °C (2 mL/mmol) and 1 equiv of phenyl isocyanate
was added dropwise. The mixture was stirred at 30-50 °C for
1 h. The precipitate was isolated, dried and recrystallized from
DMF/methanol.
N-Phenyl-N′-(quinazolin-4-yl)urea (5a). The reaction
was carried out at room temperature: yield 79%; mp 238-
239 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä
7.10 (t, 3J4′3′ ) 6.9 Hz, 1H, ArH), 7.37 (t, 3J2′3′ ) 7.9 Hz. 2H,
ArH), 7.68-7.22 (m, 3H, ArH & H6), 7.85-7.96 (m, 2H, H7 &
H8), 8.68-8.82 (m, 2H, H5 & H2), 14.08 (bs, 1H, NH). Anal.
(C15H21N4O) C, H, N.
N-Phenyl-N′-[2-(2-pyridyl)quinazolin-4-yl]urea (5b). The
reaction temperature was 50 °C: yield 85%; mp 260-262 °C;
1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä 7.09 (t,
3J4′′3′′ ) 7.3 Hz, 1H, ArH), 7.45 (t, 3J2′′3′′ ) 8.0 Hz, 2H, ArH),
7.60-7.94 (m, 5H, ArH, H8, H6 & H7), 8.06 (m, 1H, H4′), 8.24
(ddd, 3J5′4′ ) 8.8 Hz, 3J5′6′ ) 8.3 Hz, 4J5′3′ ) 1.1 Hz, 1H, H5′),
8.65 (dd, 3J56 ) 7.8 Hz, 4J57 ) unsolved, 1H, H5), 8.74 (dd,
3J6′5′ ) 8.4 Hz, 4J6′4′ ) 1.4 Hz, 1H, H6′), 8.84 (ddd, 3J3′4′′ ) 4.9
Hz, 4J3′5′ ) 1.0 Hz, 1H, H3′), 10.12 (bs, 1H, NH) and 13.08 (bs,
1H, NH). Anal. (C20H15N5O) C, H, N.
N-[2-(1,1-Dimethylethyl)quinazolin-4-yl]-N′-phenyl-
urea (5c). The reaction was carried out at room tempera-
ture: yield 73%; mp 260-261 °C dec; 1H NMR (DMSO-d6, ref
DMSO-d5-H ) 2.49 ppm) ä 1.49 (s, 9H, CH3), 7.08-7.22 (m,
1H, H8), 7.42 (dd, 3J67 ) unsolved, 3J65 ) unsolved, 1H, H6),
7.62-7.66 (m, 4H, H7 and ArH), 7.80-7.99 (m, 2H, ArH), 8.71
(d, 3J56 ) 8.6 Hz, 1H, H5), 10.48 (bs, 1H, NH) and 12.39 (bs,
1H, NH). Anal. (C19H20N4Oâ0.3MeOH) C, H, N.
N-Phenyl-N′-[(2-phenyl)quinazolin-4-yl]urea (5d). The
reaction was carried out at room temperature: yield 81%; mp
251-253 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm)
ä 7.11-7.23 (m, 2H, ArH), 7.39-7.47 (m, 3H, ArH), 7.61-7.69
(m, 6H, ArH & H8 & H6 & H7), 7.99 (d, 3J56 ) 8.5 Hz, 1H,
H5), 8.30-8.48 (m, 2H, ArH), 10.62 (bs, 1H, NH), and 12.26
(bs, 1H, NH). Anal. (C21H16N4O) C, H, N.
N-Phenyl-N′-[2-(3-pyridyl)quinazolin-4-yl]urea (5e). The
reaction temperature was 50 °C: yield 76%; mp 247 °C; 1H
NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä 7.15 (t, 3J4′′3′′
)7.0 Hz, 1H, ArH), 7.43 (t, 3J2′′3′′ ) 7.5 Hz, 2H, ArH), 7.65-
7.73 (m, 4H, H8, H5′, H6 & H7), 7.98-8.02 (m, 2H, ArH),
8.68-8.79 (m, 3H, H4′, H6′ & H5), 9.54 (bs, 1H, H2′), 10.66
(bs, 1H, NH) and 11.94 (bs, 1H, NH). Anal. (C20H15N5Oâ
0.2MeOH) C, H, N.
N-Phenyl-N′-[2-(4-pyridyl)quinazolin-4-yl]urea (5f). The
reaction temperature was 50 °C: yield 74%; mp 251 °C; 1H
NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä 7.15 (t, 3J4′′3′′
) 6.9 Hz, 1H, ArH), 7.44 (t, 3J2′′3′′ ) 7.9 Hz, 2H, ArH), 7.66-
7.82 (m, 3H, H8, H6 & H7), 8.03-8.06 (m, 2H, ArH), 8.27 (d,
3JAB ) 6.0 Hz, 2H, AA′BB′ ArH), 8.77 (d, 3J56 ) 8.3 Hz, 1H,
H5), 8.86 (d, 3JBA ) 5.9 Hz, 2H, AA′BB′ ArH), 10.70 (bs, 1H,
NH) and 11.90 (bs, 1H, NH). Anal. (C20H15N5Oâ0.2MeOH) C,
H, N.
N-[2-(6-Methyl-2-pyridyl)quinazolin-4-yl]-N′-phenyl-
urea (5g). The reaction was carried out at room tempera-
ture: yield 69%; mp 243 °C dec; 1H NMR (DMSO-d6, ref
DMSO-d5-H ) 2.49 ppm) ä 2.55 (s, 3H, CH3), 6.95 (t, 3J4′′3′′ )
7.0 Hz, 1H, ArH), 7.31-7.53 (m, 4H, ArH, H5′ & H7), 7.75-
7.92 (m, 3H, H6 & ArH), 8.04-8.18 (m, 3H, H8, H5 & H4′),
8.88 (d, 3J3′4′ ) 8.0 Hz, 1H, H3′), 10.75 (bs, 1H, NH) and 13.43
(s, 1H, NH). Anal. (C21H17N5O) C, H, N.
N-[(4,6-Dimethylpyrimidin-2-yl)quinazolin-4-yl]-N′-
phenylurea (5h). The reaction was carried out at room
temperature: yield 78%; mp 260 °C; 1H NMR (DMSO-d6, ref
DMSO-d5-H ) 2.49 ppm) ä 2.55 (s, 6H, CH3), 6.95 (t, 3J4′′3′′ )
7.9 Hz, 1H, H4′′), 7.30-7.61 (m, 2H, H3′′), 7.63-7.85 (m, 1H,
H7), 7.89-8.05 (m, 2H, H2′′), 8.20 (m, 1H, H6), 8.45 (d, 3J87 )
8.1 Hz, 1H, H8), 8.79 (d, 3J56 ) 8.3 Hz, 1H, H5), 10.71 (bs, 1H,
NH) and 13.59 (bs, 1H, NH). Anal. (C21H18N6O) C, H, N.
N-[2-(2-Furyl)quinazolin-4-yl]-N′-phenylurea (5i). The
reaction was carried out at room temperature: yield 74%; mp
230 °C dec; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm)
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ä 6.82 (dd, 3J4′5′ ) 3.4 Hz, 3J4′3′ ) 1.8 Hz, 1H, H4′), 7.14-7.23
(m, 1H, H4′′), 7.41-7.49 (m, 3H, H5′ and H3′′), 7.64 (ddd, 1H,
H7), 7.78 (d, 2H, H2′′), 7.92-7.96 (m, 2H, H8 & H6), 8.14 (sd,
3J3′4′ ) 1.7 Hz, 1H, H3′), 8.74 (d, 3J56 ) 8.2 Hz, 1H. H5), 10.65
(bs, 1H, NH) and 12.81 (s, 1H, NH). Anal. (C19H14N4O2â
0.1MeOH) C, H, N.
N-(2-Diethylaminoquinazolin-4-yl)-N′-phenylurea (5j).
The reaction was carried out at room temperature: yield 77%;
mp 211 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm)
ä 1.20 (t, 3J ) 7.0 Hz, 6H, CH3), 3.70 (q, 3J ) 7.0 Hz, 4H, CH2),
7.11-7.16 (m, 3H, H7 & ArH), 7.34-7.42 (m, 2H, H6 & ArH),
7.55-7.66 (m, 3H, H8 & ArH), 8.40 (d, 3J56 ) 7.8 Hz, 1H, H5),
10.15 (bs, 1H, NH) and 11.59 (s, 1H, NH). Anal. (C19H21N5O)
C, H, N.
N-Phenyl-N′-[(2-pyrrolidin-1-yl)quinazolin-4-yl]urea
(5k). The reaction was carried out at room temperatur: yield
76%; mp 238 °C dec; 1H NMR (DMSO-d6, ref DMSO-d5-H )
2.49 ppm) ä 1.88 (bs, 4H, CH2), 3.53 (bs, 4H, CH2), 7.05-7.19
(m, 2H, H7 & ArH), 7.29-7.48 (m, 3H, H6 & ArH), 7.52-7.67
(m, 3H, H8 & ArH), 8.51 (d, 3J56 ) 7.9 Hz, 1H, H5), 10.22 (bs,
1H, NH), and 11.99 (s, 1H, NH). Anal. (C19H19N5O) C, H, N.
General Procedure for the Preparation of 8a-b,d. One
equivalent of 6 was dissolved in acetonitrile at 50 °C (5 mL/
mmol) and a solution of 1 equiv of phenyl isocyanate (7i) in
acetonitrile was added (2 mL/mmol) (3-mmol scale). The
mixture was stirred at 50 °C for 1 h. The precipitate was
isolated, washed several times with subsequently acetonitrile,
methanol, and petroleum ether, dried and recrystallized.
N-Phenyl-N′-(isoquinolin-1-yl)urea (8a). Recrystalliza-
tion from DMF/EtOH yielded 99% of white crystals: mp 221-
223 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H ) 2.49 ppm) ä
7.07 (t, 3J4′3′ ) 7.3 Hz, 1H, ArH), 7.36 (t, 3J3′2′ ) 7.8 Hz, 2H.
ArH), 7.49 (d, 3J3,4 ) 5.8 Hz, 1H, H3), 7.61-7.73 (m, 3H, H7
& ArH), 7.76-7.84 (m, 1H, H6), 7.94 (d, 3J87 ) 8.2 Hz, 1H,
H8), 8.22 (d, 3J43 ) 5.8 Hz, 1H, H4), 8.70 (d, 3J56 ) 8.3 Hz,
H5), 9.96 (bs, 1H, NH), and 12.70 (bs, 1H, NH). Anal.
(C16H13N3O) C, H, N.
N-Phenyl-N′-[3-(2-pyridyl)isoquinolin-1-yl]urea (8b).
Recrystallization from DMF/MeOH yielded 98% of yellow/
white crystals: mp 228 °C; 1H NMR (DMSO-d6, ref DMSO-
d5-H ) 2.49 ppm) ä 7.40-7.58 (m, 3H, ArH), 7.61 (m, 1H, H4′),
7.67-7.92 (m, 4H, ArH & H6 & H7), 8.02-8.16 (m, 2H, H3′ &
H5′), 8.30 (dd, 3J87 ) 8.0 Hz, 4J86 ) unsolved, 1H, H8), 8.41 (s,
1H, H4), 8.74 (d, 3J56 ) 8.6 Hz, 1H, H5), 8.83-8.88 (m, 1H,
H6′), 10.15 (bs, 1H, NH), and 13.09 (bs, 1H, NH). Anal.
(C21H16N4Oâ0.3MeOH) C, H, N.
N-Phenyl-N′-(3-phenylisoquinolin-1-yl)urea (8d). Re-
crystallization from DMF/MeOH yielded 98% of yellow/white
crystals: mp 250-251 °C; 1H NMR (DMSO-d6, ref DMSO-d5-H
) 2.49 ppm) ä 7.42-7.62 (m, 3H, ArH), 7.71-7.94 (m, 9H, ArH
& H6 & H7), 8.26 (dd, 3J87 ) 7.9 Hz, 4J86 ) unsolved, 1H, H8),
8.39 (s, 1H, H4), 8.70 (d, 3J56 ) 8.4 Hz, 1H, H5), 10.04 (bs, 1H,
NH), and 12.89 (bs, 1H, NH). Anal. (C22H17N3Oâ0.2MeOH) C,
H, N.
General Procedure for the Preparation of 9a-h, 10a,b,
and 11. One equivalent of 2-phenyl-4-quinazolineamine (4d)
was dissolved in acetonitrile at 30-50 °C (5 mL/mmol) and a
solution of 1 equiv of isocyanate 7 in acetonitrile was added
(2 mL/mmol). The mixture was stirred at 30-50 °C for 0.5-4
h. The precipitate was isolated, washed several times with
different solvents, dried and recrystallized.
N-(4-Chlorophenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9a): yield 88%; mp 291-292 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 6.51 (d, 3JAB ) 8.8 Hz, 2H,
AA′BB′ ArH), 7.01 (d, 3JBA ) 8.7 Hz, 2H, AA′BB′ ArH), 7.47-
7.62 (m, 2H, H6 and H7), 7.62-7.76 (m, 3H, H3′, H4′, and H5′),
8.24 (dd, 3J87 ) 8.3 Hz, 4J86 ) unsolved, 1H, H8), 8.43-8.46
(m, 2H, H2′ and H6′), 8.73 (dd, 3J56 ) unsolved, 4J57 )
unsolved, 1H, H5), 10.70 (bs, 1H, NH), and 12.29 (bs, 1H, NH).
Anal. (C21H15ClN4O) C, H, N.
N-(4-Methylphenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9b): yield 66%; mp 258-260 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 3.61 (s, 3H, CH3), 6.50 (d, 3JAB
) 8.9 Hz, 2H, AA′BB′ ArH), 6.63 (d, 3JBA ) 8.9 Hz, 2H, AA′BB′
ArH), 7.51-7.92 (m, 5H, H6, H7, H3′, H4′, and H5′). 8.24 (d,
3J87 ) 8.0 Hz, 1H, H8), 8.43-8.55 (m, 2H, H2′ & H6′), 8.70
(dd, 3J56 ) unsolved, 4J57 ) unsolved, 1H, H5), 10.58 (bs, 1H,
NH), and 12.19 (bs, 1H, NH). Anal. (C22H18N4Oâ0.2MeOH) C,
H, N.
N-(3,4-Dichlorophenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9c): yield 81%; mp 282-284 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 7.16-7.21 (m, 3H, ArH), 7.47-
7.50 (m, 2H, H6 and H7), 7.75-7.84 (m, 5H, H2′, H3′, H4′,
H5′, and H6′), 8.24 (dd, 3J87 ) 8.2 Hz, 4J86 ) unsolved, 1H,
H8), 8.45 (dd, 3J56 ) 8.7 Hz, 4J57 ) 1.9 Hz, 1H, H5), 10.69 (bs,
1H, NH), and 12.32 (bs, 1H, NH). Anal. (C21H14Cl2N4Oâ
0.3MeOH) C, H, N.
N-(4-Methoxyphenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9d): yield 72%; mp 259-261 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 3.77 (s, 3H, OCH3), 7.01 (d, 3J2′′3′′
) 9.0 Hz, 4H, ArH), 7.56-7.60 (m, 5H, H6, H7, H3′ & H4′),
7.97 (dd, 3J87 ) unsolved, 4J86 ) unsolved, 1H, H8), 8.37-8.42
(m, 2H, H2′), 8.76 (dd, 3J56 ) unsolved, 4J57 ) unsolved, 1H,
H5), 10.56 (bs, 1H, NH), and 12.15 (bs, 1H, NH). Anal.
(C22H18N4O2â0.3MeOH) C, H, N.
N-(3-Methoxyphenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9e): yield 57%; mp 255-258 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 3.79 (s, 3H, OCH3), 6.70-6.74
(m, 1H, H4′′), 7.27-7.38 (m, 3H, H2′′, H5′′, and H6′′), 7.62-
7.70 (m, 5H, H6, H7, H3′ & H4′), 7.99 (dd, 3J87 ) unsolved,
4J86 ) unsolved, 1H, H8), 8.39-8.41 (m, 2H, H2′), 8.75 (dd,
3J56 ) 8.4 Hz, 4J57 ) unsolved, 1H, H5), 10.60 (bs, 1H, NH),
and 12.28 (bs, 1H, NH). Anal. (C22H18N4O2â0.2H2O) C, H, N.
N-(2-Methoxyphenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9f): yield 32%; mp 227-229 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 3.62 (s, 3H, OCH3), 7.00-7.13
(m, 4H, ArH), 7.51-7.69 (m, 3H, H3′, ArH, and H5′), 7.97-
7.99 (m, 2H, H6 and H7), 8.19 (dd, 3J87 ) 8.1 Hz, 4J86 )
unsolved, 1H, H8), 8.45-8.49 (m, 2H, H4′ and H6′), 8.77 (dd,
3J56 ) 8.5 Hz, 4J57 ) unsolved, 1H, H5), 10.58 (bs, 1H, NH),
and 11.89 (bs, 1H, NH). Anal. (C22H18N4O2â0.2H2O) C, H, N.
N-(2-Chlorophenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9g): yield 69%; mp 233-234 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 7.17 (t, 3J4′′3′′ ) 6.9 Hz, 1H, H4′′),
7.35-7.58 (m, 5H, H3′, H2′′ & H3′′), 7.62-7.74 (m, 1H, H5′),
7.92-8.01 (m, 2H, H4′ & H8), 8.13 (d, 3J6′5′ ) 7.1 Hz, 1H, H6′),
8.28-8.46 (m, 2H, H6 & H7), 8.77 (d, 3J56 ) 7.3 Hz, 1H, H5),
10.78 (bs, 1H, NH), and 11.99 (bs, 1H, NH). Anal. (C21H15-
ClN4Oâ0.2MeOH) C, H, N.
N-(2-Methylphenyl)-N′-(2-phenylquinazolin-4-yl)-
urea (9h): yield 45%; mp 120-121 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 2.18 (s, 3H, CH3), 7.05-7.32
(m, 3H, ArH), 7.48-7.56 (m, 3H, ArH), 7.60-7.78 (m, 2H, H6
& H7), 7.89-8.03 (m, 2H, ArH), 8.23-8.30 (m, 2H, H8 & H6′),
8.78 (d,3J56 ) 8.2 Hz 1H, H5), 10.62 (bs, 1H, NH), and 11.71
(bs, 1H, NH). Anal. (C22H18N4Oâ0.2MeOH) C, H, N.
N-(2-Methoxyphenyl)-N′-[2-(3-pyridyl)quinazolin-4-yl]-
urea (10a): yield 77%; mp 257-258 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 3.62 (s, 3H, OCH3), 6.98-7.15
(m, 3H, H3′′, H4′′ & H5′′), 7.62-7.79 (m, 2H, H6 & H7), 8.03
(m, 2H, H5′ & H6′′), 8.11 (d, 3J87 ) 8.4 Hz, 1H, H8), 8.71-
8.83 (m, 3H, H4′, H6′ & H5), 9.61 (s, 1H, H2′), 10.65 (bs, 1H,
NH), and 11.80 (bs, 1H, NH). Anal. (C21H17N5O2) C, H, N.
N-(2-Methylphenyl)-N′-[2-(3-pyridyl)quinazolin-4-yl]-
urea (10b): yield 50%; mp 227-228 °C; 1H NMR (DMSO-d6,
ref DMSO-d5-H ) 2.49 ppm) ä 2.19 (s, 3H, CH3), 7.14-7.27
(m, 3H, H5′ & ArH), 7.61-7.81 (m, 3H, H8, H6 & H7), 8.02-
8.04 (m, 2H, ArH), 8.62 (d, 3J56 ) 8.0 Hz, 1H, H5), 8.74-8.82
(m, 2H, H4′ & H6′), 9.41 (s, 1H, H2′), 10.70 (bs, 1H, NH), and
11.50 (s, 1H, NH). Anal. (C21H17N5O) C, H, N.
N-(2-Methoxyphenyl)-N′-[2-(2-pyridyl)quinazolin-4-yl]-
urea (11): yield 68%; mp 190 °C; 1H NMR (DMSO-d6, ref
DMSO-d5-H ) 2.49 ppm) two isomeric forms A:B ) 4:1, A ä
3.40 (s, 3H, OCH3), 6.98-7.10 (m, 4H, ArH), 7.55-8.14 (m,
5H, H4′, H5′, H6, H7 & H8), 8.39-8.43 (m, 1H, H3′), 8.77-
8.84 (m, 2H, H6′ & H5), 10.65 (bs, 1H, NH), and 12.29 (bs,
1H, NH), B ä 3.90 (s, 3H, OCH3), 6.98-7.10 (m, 4H, ArH),
7.55-8.11 (m, 5H, H4′, H5′, H6, H7 & H8), 8.52-8.56 (m, 1H,
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H3′), 8.77-8.84 (m, 2H, H6′ & H5), 10.65 (bs, 1H, NH), 14.90
(bs, 1H, Nâ â âHâ â âO). Anal. (C21H17N5O2) C, H, N.
Molecular Modeling. Calculations were performed with
SPARTAN version 5.0 (Wavefunction, Inc., Irvine, CA)33
running on a Silicon Graphics O2 workstation. The Merck force
field was used in molecular mechanics minimizations.
Correlation Analysis. Thirteen descriptors for aromatic
substituents were used in the correlation analysis for com-
pounds 5a-k and 9: namely óm, óp, ó0, ó-, ó+, ð, log P, (log
P)2, Es, L, B1, Bmax, and MR.33 No correlation was observed
between the A3 receptor binding affinity and the descriptors
other than Bmax. Data analysis was with Microsoft Excel
version 5.0 (Microsoft Corp.) running on MacOS 8.5.
Pharmacology. Materials. [3H]cAMP, [3H]DPCPX, and
[3H]CGS 21680 were commercially available from DuPont
Nemours (‘s Hertogenbosch, The Netherlands) with specific
activities of 31, 120, and 38.3 Ci/mmol, respectively. [125I]AB-
MECA was prepared as described by Olah et al.31 Adenosine
deaminase was from Boehringer Mannheim (Mannheim,
Germany). Forskolin was purchased from Sigma (The Neth-
erlands) and XAC from Research Biochemicals International
(Natick, MA). CGS 15943 was a gift from Dr. M. Williams and
Dr. J. Watthey (Ciba-Geigy, Summit) and L-249313 was a gift
form Dr. M. Jacobson (Merck). CHO cells expressing the
human adenosine A3 receptor were obtained from Dr. S. Rees
(Glaxo Wellcome, U.K.) and HEK 293 cells stably expressing
the human adenosine A3 receptor were a gift from Dr. K.-N.
Klotz (University of Wu¨rzburg, Germany).
Methods for Receptor Binding and Adenylase Cyclase
Measurement. Binding of [3H]DPCPX to adenosine A1 recep-
tors on rat cerebral cortex membranes and of [3H]CGS 21680
to adenosine A2A receptors from rat striatal membranes was
performed as described previously.28,29 Binding of [125I]AB-
MECA to membranes of HEK 293 cells stably expressing the
human adenosine A3 receptor was determined as described.30,31
cAMP production was assayed in CHO cells stably expressing
the human adenosine A3 receptor. Assays were performed in
DMEM/HEPES buffer (adjusted to pH 7.4, at 25 °C). The
method involved addition of the ligand to membranes in the
presence of ADA (10 IU/mL), NECA as agonist, forskolin (10
íM) to stimulate adenylate cyclase, and rolipram and cilos-
tamide (50 íM each) as phosphodiesterase inhibitors. The
reaction was terminated by addition of ice-cold 0.1 N HCl.
cAMP determination was done via [3H]cAMP and incubation
for 2.5-18 h at 0 °C with protein kinase A. After filtration
over Whatman GF/C filters using a Brandell cell harvester
(Brandell, Gaithersburg, MD) under reduced pressure (200
mbar), the radioactivity was determined in a LKB1219 counter.
The IC50 values and pA2 were calculated using Prism (Graph-
Pad, SanDiego, CA).
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